phone: +48 22 721 40 00   /  fax: +48 22 721 13 33  /

Management of the Company



Management Board


Robert Neymann - President of the Management Board

In the years 1982-1987, Mr. Robert Neymann studied at the Warsaw School of Economics (major subject: Finance).

Mr. Robert Neymann worked successively:1987 to 1990, at OMC Poll Ltd. as a financial comptroller at the Controlling Department; − Sales Manager for the Blendax product line in Poland;

  • 1990 to 1991, at Procter & Gamble Polska as National Key Account Manager;
  • 1991 to 1993, at Procter & Gamble Polska as Unit Sales Manager (Northern Poland);
  • 1993 to 1994, at Procter & Gamble Polska as Trade Marketing Manager;
  • 1994 to 1996, at Procter & Gamble Polska as District Sales Manager (Central and Northern Poland);
  • 1996 to 1999, at Procter & Gamble Central and Eastern Europe as Distributor Operations Manager Cⅇ
  • 1999 to 2000, at Procter & Gamble Western Europe as Laundry Additives Customer Business Development Manager Western Europe;
  • 2001 to 2005, at Herbapol Lublin S.A. as Vice President of the Management Board for Commercial Affairs;
  • 2005 to 2007, at Polsnack Sp. z o.o. as President of the Management Board;
  • 2009 to 2011, at Harper Trade Sp. z o.o. as President of the Management Board;
  • 2007 to 2017, at Harper Hygienics S.A. as President of the Management Board.


Adam Polonek – Member of the Management Board

Mr. Adam Polonek is a graduate of the University of Economics in Katowice. He has extensive knowledge and experience in managing finances of companies and capital market. Since 2006 he has been an employee of BIOTON S.A. where he was holding first the position of deputy Chief Financial Officer and then the position of Chief Financial Officer. During this time he had the opportunity to improve his knowledge and competence in managing finances of the company, debt funding, development projects and restructuring transactions. Is also performing shareholding supervision in the subsidiaries of BIOTON S.A. In 20002006 was employed at CAIB Financial Advisers (at present UniCredit CAIB Poland), holding the positions from an analyst to a deputy director, where he was dealing with consultancy in mergers and acquisitions, evaluation of enterprises and optimization of financing structures. He has participated in a number of training within the scope of international accounting standards, evaluation of enterprises and project management. He is fluent in English. Since
20 December 2011 he has been holding the function of a Member of the Management Board of BIOTON S.A.


Supervisory Board


Mr. Jubo Liu – President of the Supervisory Board

Mr. Jubo Liu is the founder and has served as the CEO of Cogenes Biotechnology Incorporation (focused on in vitro diagnosis R&D, manufacturing and marketing) since August 2011 and served as the CEO of NovoTek Pharmaceuticals Limited (Hong Kong) and NovoTek Therapeutics Inc (Beijing) (international platform to globalize healthcare products both from within and outside of China) from August 2009 to March 2018. From April 2008 to July 2009 he was the China Chief Representative of Immtech Pharmaceuticals Inc. (US New York) (establishing Chinese activity infrastructure and investment plans). From November 2007 to April 2008, he acted as a Clinical Trial Liaison with US-based Pharmaceuticals Inc. (US New York) (carrying out global clinical trial operation in China). From October 2006 to November 2007 he was a scientist at Boston Vertex Pharmaceuticals Inc. (formulation and drug delivery). From July of 2005 to January of 2007 he was as a cofounder and served as the Director of Business Development of JCS Biopolytech Incorporation (modified biopolymer R&D and marketing used for drug delivery and nanotechnology). From August 1997 to February 2001, he served as the Director of Marketing and Regulatory Affairs for Huayuanlong Medicinal Technology Development Co. Ltd. of Beijing, China. Mr. Liu obtained his Bachelor's Degree in Pharmacy from the Department of Pharmacy of the Pharmaceutical University of Shenyang (September 1992 to July 1997) and a Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto (from September 2002 to October 2006). Furthermore, Mr. Liu is an author or co-author of several publications regarding medical and biological issues.


Mr. Dariusz Trzeciak – Vice President of the Supervisory Board

Mr. Dariusz Trzeciak has completed 4-year PhD studies at the Law and Administration Faculty of the University of Warsaw, Postgraduate MBA Studies at the Warsaw School of Economics and Law and Administration Faculty and History Faculty of the University of Warsaw. In the past, he held managerial and supervisory positions in many companies, including the function of the President of the Management Board of Towarzystwo Ubezpieczeń na Życie Polisa Życie S.A., Sferia S.A., IT Polpager S.A. At present, he holds the position of: a Member of the Management Board of Sferia S.A., a Member of the Management Board of Aero 2 Sp. z o.o. and Vice-Chairman of the Supervisory Board of Muzo FM Sp. z o.o. (formerly Radio PIN) and member of the Supervisory Board of Altalog Sp. Z o.o.. He is also a member of elected bodies in professional organizations and chambers of commerce.


Dr Ramesh Rajentheran - Vice President of the Supervisory Board

Dr Ramesh Rajentheran is the Founder & CEO of AlleleHealth Pte Ltd, Singapore since August 2018. Since 2015 to August 2018 Dr Ramesh Rajentheran was the Group Chief Financial Officer and Group Chief Operating Officer at Fullerton Health (FHC) in Singapore. From 2011 to 2015 Dr Ramesh Rajentheran was hired as the Managing Director, Head - Asian Healthcare Investment Banking at Barclays, Investment Banking Division, Singapore/Hong Kong. Between 2010 and 2011, Dr Ramesh Rajentheran was the Head of Markets & Equities and Senior Advisor to Executive Chairman at Hong Leong Group, Kuala Lumpur, Malaysia. Since 2009 to 2010 Dr Ramesh Rajentheran was working at Barclays Capital, London, UK as the Director- Global Healthcare Industry Specialist, Equities. From 2006 -2009 Dr Ramesh Rajentheran was the Executive Director- Global Healthcare Specialist Sales, Equities at Morgan Stanley, London, UK. In 2004, Dr Ramesh Rajentheran obtained MBA diploma in finance at London Business School and Bachelor's Degree in 1999 at Newcastle Medical School, Newcastle, UK.


Mr. Vaidyanathan Viswanath – Member of the Supervisory Board

Mr. Vaidyanathan Viswanath is a post-graduate in Pharmacology with about 3 decades experience in sales, marketing, business development and strategic planning in the pharmaceutical industry across Asia. His previous experience includes Serum Institute (Serono) and Astra in India both in sales and marketing, 8 years with Pharmacia in India and China. Mr. Vaidyanathan Viswanath was then the BD and Strategic Planning Director for Pfizer China and BD Director - Asia for Capsugel (Division of Pfizer) until 2011 based in Bangkok. Currently living in Beijing, Mr. Vaidyanathan Viswanath is an Independent Consultant for a number of pharma companies and in this role offers his expertise in the area of Strategic Marketing, Business Development, Marketing and Sales Effectiveness, Alliance Management, KOL & Advocacy development. With his deep understanding of the trends in the industry backed up by his strong networking capabilities, Mr. Vaidyanathan Viswanath envisions to act as a bridge for these companies to reach out to companies overseas and visa versa.


Ph. D. Hao Fan - Member of the Supervisory Board

Dr Hao received his Ph.D. degree in 1995 from Nagoya University in Japan. He underwent his postdoctoral training at the National Institute of Health(NIH), Laboratory of Molecular Growth Regulation- Institute of Child Health and Human Development from 1995-1997 in Maryland, US.

He then moved to the private sector and served as the Director of Product Development and Manufacturing at Eden Bioscience Co. Ltd, USA until 2006.

In 2001 he was awarded the Presidential Green Chemistry Challenge Award by the EPA in the USA recognizing his contribution to developing and industrializing Eden’s bio-products.

Dr Fan has published over 20 peer-reviewed academic papers including one of the most famous Journal,CELL. In his carrier, he has also been awarded many patents during his extensive research experience.

Since 2007, Dr Fan has focused on industrial scale production of biopharmaceutical products including insulin and its analogues. He has raised almost 100 million US dollars founding several bio-companies engaged in commercializing biopharmaceutical and biomaterial products.

He currently serves as the board chairman of Sinhao Science and Technology Co., Ltd in Singapore.


Mr. Nicola Cadei- Member of the Supervisory Board

Professional profile:

Over 25 year of diverse leadership experience in the pharmaceutical industry with increasing levels of responsibilities. Extensive experience in finance, sales & marketing, contract development and manufacturing, strategy development, business restructuring and transactions. During his professional career he gained strong experience and skills:

In-depth understanding of the Italian and International pharmaceutical market.

Effective management of pharmaceutical development and manufacturing activities with a continuous effort towards improvement of productivity and customers’ relationship.

Management of Sales and Marketing. Launch of products and new indications. Drawing up and implementing strategic plans and product tactics. Good relational skills with medical Opinion Leaders and Customers.
Strong negotiation skills and knowledge of contracts in the pharmaceutical sector. Strategic planning, company re-structuring processes and M&A.

Solid financial background.

Result oriented.


Work experience:

2016- current: General Manager and Member of the Board of Directors at Pharmatex Italia srl, The company focused in the development, manufacturing and commercialization of injectable pharmaceutical products, which belongs to Yifan Pharmaceutical LTD, a leading Chinese pharmaceutical company, traded at Shenzhen stock exchange.

2010 - 2015: Chief Operating Officer (C.O.O.) at Mipharm, an Italian centre of excellence for CDMO activities, new product development and services dedicated to pharmaceutical industries. Turnover of around 45 million euro (around 50 million packs yearly manufactured) and 250 employees.

2009- 2010: Senior Advisor at Resources Global Professionals, American professional services firm. Publicly traded company (Nasdaq) with more than 4100 professionals from more than 85 practice offices. Founded in Italy in mid 2007. The role implies involvement in consultancy programmes to clients and responsibility of business development in the pharmaceutical sector.

1993 - 2008: AstraZeneca S.p.A., multinational pharmaceutical company with a total turnover in Italy of about 1 Billion euro and 1100 employees, 850 of whom in sales force. Following roles and responsibilities covered:

2006 - 2008: Commercial Operations Director

2004 - 2005: Strategic Portfolio Development & CNS Business Director

2002 – 2003: Customer, Supply Chain & Business Development Director 2000 - 2002: Sales Effectiveness Director

1995 – 2000: Finance and Control Director 1994- 1995: Senior Accountancy Manager

1993 - 1994: Reporting Manager

1990- 1993: Senior Auditor at KPMG



July 1983: High school scientific diploma,

May 1990: Degree in Economics and Commerce – specialising in Marketing – awarded by the L. Bocconi

University of Milan.

Participation in courses and stages:

  • Marketing and Sales Management, at SDA Bocconi Milano;
  • Strategic Thinking at INSEAD Paris;
  • Project Management, Business Leadership and Coaching.



Fluent in English, knowledge of French.


Mr. Wei Ming TAN - Member of the Supervisory Board

Executive summary:

  • Award winning, global / local and multi‐disciplinary C‐level executive with over 20 years of experience spanning M&A and corporate strategy, business / partnership development, investment banking / corporate venture capital / private equity, investor relations, procurement, audit, treasury and tax
  • Accomplished at all levels of internal and external stakeholder engagement (Principals, Board of Directors, CEOs / CXOs, Strategic Partners, Institutional Investors & Equity Analysts, Regulators)
  • Proven track record of high achievement in both public and private company (spectrum of start‐ up to growth and mature stage) environments
  • Diversified skillsets gained in media and entertainment / banking and financial services / pharmaceutical / accounting industries
    • Capital markets, debt/equity raisings, mergers and acquisitions, JVs and divestitures;
    • Driving business development / growth initiatives coupled with generation of cost savings and improvement in efficiencies / productivity to achieve value creation;
    • Observing, strategizing and translating big picture vision into hands‐on practical execution;
    • Leading large cross divisional / functional teams to achieve strategic, transformational goals;
    • Developing all levels of talent into senior leaders and formation of high performing teams.


 Career profile:


Chief Financial Officer

Responsible for all financial, risk and capital functions encompassing the entire International Division of Shenzhen‐listed Yifan Pharmaceutical Co. Ltd. Oversees all finance and accounting matters, including corporate finance, portfolio management, tax and treasury; as well as procurement, legal and human capital.


Chief Investment Officer

Responsible for Astro’s financial, capital and investment management, and led successful IPO of the company on Bursa Malaysia. Oversaw all group strategy, corporate finance, venture capital and business development activities, portfolio management, as well as strategic partnerships and procurement. Previously also responsible for investor relations, business advisory, treasury and tax divisions


Director; Telecom, Media and Gaming Industry Group

Trusted strategic and financial advisor to Boards / CEOs / CFOs / Heads of M&A at companies, and Partners / MDs / Principals at global private equity firms. Clients included Liberty Global, Ziggo, Digicel, American Tower, Helios, BC Partners, Mid Europa Partners and Warburg Pincus

Vice President; Financial Sponsors Group

Led execution of leveraged buyouts, refinancing and exits for private equity clients (inter alia client and management interaction, credit analysis and due diligence, financial modelling, debt structuring, term sheet and documentation negotiation, transaction execution and syndication)


Senior Associate; Leveraged Finance


Investment Associate; Macquarie Direct Investment (Private Equity Division) Chief Financial Officer; Macquarie Direct Investment (Private Equity Division) Project Manager; Treasury and Commodities Division


Corporate Treasury & Projects Manager


Senior Analyst; Audit Division




Master of Business Administration (Finance major)

  • Founding Director, Coller Institute for Private Equity; President of 750‐member strong Private Equity Club and Co‐Chair of inaugural 2003 LBS Private Equity Conference (profits of c.£50,000)
  • Co‐authored specially commissioned report on private equity secondary market entitled "Routes to Liquidity". Report published by Private Equity International magazine in April 2004


Graduate Diploma in Applied Finance and Investment


Chartered Accountant designation

  • Merit Prize for Taxation module (top 5% of candidates globally)


Bachelor of Commerce (Finance and Accounting majors)

  • Employment sponsorship by Deloitte & Touche (1 of 2 successful applicants from over 200)

© 2019 BIOTON S.A.